NVIV - InVivo Therapeutics Holdings Corp.
| Previous Close | 1.4500 |
| Open | 1.5200 |
| Bid | 1.4300 x 1400 |
| Ask | 1.5000 x 800 |
| Day's Range | 1.3500 - 1.5500 |
| 52 Week Range | 1.3400 - 15.1900 |
| Volume | 91,348 |
| Avg. Volume | 62,756 |
| Market Cap | 13.687M |
| Beta (3Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.6940 |
| Earnings Date | May 2, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire•yesterday
InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
InVivo Therapeutics Holdings Corp. (NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, “Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury”, co-authored by Kee Kim, M.D., Department of Neurosurgery, UC-Davis, Sacramento, CA, K. Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, Greenville, NC, Lee, Domagoj Coric, M.D., Carolina Neurosurgery and Spine, Charlotte, NC, Nicholas Theodore M.D., Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, and Richard Toselli, M.D., President and Chief Executive Officer of InVivo.
- Business Wire•17 days ago
InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update
InVivo Therapeutics Holdings Corp. today reported financial results for the year ended December 31, 2018.
- Business Wire•3 months ago
InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
InVivo Therapeutics Holdings Corp. (NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective January 14, 2019. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology.
- Business Wire•5 months ago
InVivo Therapeutics to Present at the LD Micro Main Event on Tuesday December 4th, 2018
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the LD Micro Main Event on Tuesday, December 4, 2018 at 7:30 am Pacific Time at the Luxe Hotel in Los Angeles, CA .
- GlobeNewswire•5 months ago
Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Associated Press•5 months ago
InVivo: 3Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 42 cents. In the final minutes of trading on Thursday, the company's shares hit $2.09. A year ago, they were trading ...
- Business Wire•5 months ago
InVivo Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
- Announces Western Institutional Review Board Approval for Select INSPIRE 2.0 Study Sites -
- Business Wire•7 months ago
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.
- Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells -
- Business Wire•7 months ago
InVivo Therapeutics Announces Publication of Neuro-Spinal Scaffold Preclinical Data in Peer-Reviewed Journal Biomaterials
- Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold -
- Business Wire•7 months ago
InVivo Therapeutics Announces Presentation at the Ladenburg Thalmann 2018 Healthcare Conference and Provides Business Update
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New York. Dr. Toselli’s presentation will discuss recent company updates, including updates related to the Company’s INSPIRE 2.0 Study. A live webcast will be available at http://wsw.com/webcast/ladenburg4/nviv/, and a webcast replay will be available at the same address approximately one hour after the live webcast presentation.
- Business Wire•8 months ago
InVivo Therapeutics Announces Complete 12-Month Data from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
InVivo Therapeutics Holdings Corp. (NVIV) today announced the complete 12-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). As previously announced by InVivo, 7 of 16 (44%) patients who reached the six-month primary endpoint visit in the INSPIRE study had an ASIA Impairment Scale (AIS) conversion at 6 months, which is the primary endpoint of the trial (defined as improvement in AIS grade from baseline for all evaluable patients at the six-month visit). The Objective Performance Criterion (OPC) (study success definition) for the study was a 25% AIS conversion rate based on the published conversion rates for thoracic spinal cord injury (SCI) reported in the literature.
- Associated Press•8 months ago
InVivo: 2Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of $7.48 per share. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $50. _____ ...
- Business Wire•8 months ago
InVivo Therapeutics Reports 2018 Second Quarter Financial Results
- Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59% -
- Business Wire•10 months ago
InVivo Therapeutics Announces Closing of $15.2 Million Public Offering, Including the Exercise of Underwriter’s Overallotment Option
InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant. In addition, the underwriter exercised its option to purchase an aggregate of 989,997 additional shares of common stock and additional warrants to purchase 989,997 shares of common stock at the public offering price of $2.00 per share and warrant, less the underwriting discounts and commissions.
- Business Wire•10 months ago
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant. The gross proceeds from this offering are expected to be $13.2 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by InVivo Therapeutics.
- Simply Wall St.•11 months ago
Is InVivo Therapeutics Holdings Corp’s (NASDAQ:NVIV) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as InVivo Therapeutics Holdings Corp (NASDAQ:NVIV) with its market cap of US$11.35M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
- Business Wire•11 months ago
InVivo Therapeutics Reports 2018 First Quarter Financial Results
InVivo Therapeutics Holdings Corp. today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018.
